LJ-1888, a selective antagonist for the A3 adenosine receptor, ameliorates the development of atherosclerosis and hypercholesterolemia in apolipoprotein E knock-out mice |
Park, Jong-Gil
(Biotherapeutics Translational Research Center, Korea Research Institute of Bioscience & Biotechnology (KRIBB))
Jeong, Se-Jin (Cardiovascular Division, Department of Medicine, Washington University School of Medicine) Yu, Jinha (College of Pharmacy, Seoul National University) Kim, Gyudong (College of Pharmacy, Seoul National University) Jeong, Lak Shin (College of Pharmacy, Seoul National University) Oh, Goo Taeg (Immune and Vascular Cell Network Research Center, National Creative Initiatives, Department of Life Sciences, Ewha Womans University) |
1 | Jacobson KA (1998) Adenosine A3 receptors: novel ligands and paradoxical effects. Trends Pharmacol Sci 19, 184-191 DOI |
2 | Borea PA, Varani K, Vincenzi F et al (2015) The A3 adenosine receptor: history and perspectives. Pharmacol Rev 67, 74-102 |
3 | Jeong LS, Choe SA, Gunaga P et al (2007) Discovery of a new nucleoside template for human A3 adenosine receptor ligands: D-4'-thioadenosine derivatives without 4'-hydroxymethyl group as highly potent and selective antagonists. J Med Chem 50, 3159-3162 DOI |
4 | Lee J, Hwang I, Lee JH, Lee HW, Jeong LS and Ha H (2013) The selective A3AR antagonist LJ-1888 ameliorates UUO-induced tubulointerstitial fibrosis. Am J Pathol 183, 1488-1497 DOI |
5 | Libby P, Ridker PM and Hansson GK (2011) Progress and challenges in translating the biology of atherosclerosis. Nature 473, 317-325 DOI |
6 | Libby P, Schoenbeck U, Mach F, Selwyn AP and Ganz P (1998) Current concepts in cardiovascular pathology: the role of LDL cholesterol in plaque rupture and stabilization. Am J Med 104, 14S-18S |
7 | Istvan ES and Deisenhofer J (2001) Structural mechanism for statin inhibition of HMG-CoA reductase. Science 292, 1160-1164 DOI |
8 | Hou R and Goldberg AC (2009) Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety. Endocrinol Metab Clin North Am 38, 79-97 DOI |
9 | Lee MR, Lim CJ, Lee YH et al (2014) The adipokine Retnla modulates cholesterol homeostasis in hyperlipidemic mice. Nat Commun 5, 4410 DOI |
10 | Nissen SE, Tuzcu EM, Schoenhagen P et al (2005) Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 352, 29-38 DOI |
11 | Davis HR Jr, Compton DS, Hoos L and Tetzloff G (2001) Ezetimibe, a potent cholesterol absorption inhibitor, inhibits the development of atherosclerosis in ApoE knockout mice. Arterioscler Thromb Vasc Biol 21, 2032-2038 DOI |
12 | Smith L, Mosley J, Yates J and Caswell L (2016) The New Face of Hyperlipidemia Management: Proprotein Convertase Subtilisin/Kexin Inhibitors (PCSK-9) and Their Emergent Role As An Alternative To Statin Therapy. J Pharm Pharm Sci : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques 19, 137-146 |
13 | Brousseau ME, Schaefer EJ, Wolfe ML et al (2004) Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 350, 1505-1515 DOI |
14 | White CR, Datta G, Zhang Z et al (2008) HDL therapy for cardiovascular diseases: the road to HDL mimetics. Curr Atheroscler Rep 10, 405-412 DOI |
15 | Writing Group M, Mozaffarian D, Benjamin EJ et al (2016) Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation 133, e38-360 |
16 | Layland J, Carrick D, Lee M, Oldroyd K and Berry C (2014) Adenosine: physiology, pharmacology, and clinical applications. JACC Cardiovasc Interv 7, 581-591 DOI |
17 | Bowser JL, Lee JW, Yuan X and Eltzschig HK (2017) The hypoxia-adenosine link during inflammation. J Appl Physiol 123, 1303-1320 DOI |
18 | Sheth S, Brito R, Mukherjea D, Rybak LP and Ramkumar V (2014) Adenosine receptors: expression, function and regulation.Int J Mol Sci 15, 2024-2052 DOI |
19 | Nelson RH (2013) Hyperlipidemia as a risk factor for cardiovascular disease. Prim Care 40, 195-211 DOI |
20 | Heseltine L, Webster JM and Taylor R (1995) Adenosine effects upon insulin action on lipolysis and glucose transport in human adipocytes. Mol Cell Biochem 144, 147-151 DOI |
21 | Bingham TC, Fisher EA, Parathath S, Reiss AB, Chan ES and Cronstein BN (2010) A2A adenosine receptor stimulation decreases foam cell formation by enhancing ABCA1-dependent cholesterol efflux.J Leukoc Biol 87, 683-690 DOI |
22 | Jones MR, Zhao Z, Sullivan CP et al (2004) A(3) adenosine receptor deficiency does not influence atherogenesis. J Cell Biochem 92, 1034-1043 DOI |
23 | Yu J, Ahn S, Kim HJ et al (2017) Polypharmacology of N(6)-(3-Iodobenzyl)adenosine-5'-N-methyluronamide (IB-MECA) and Related A3 Adenosine Receptor Ligands: Peroxisome Proliferator Activated Receptor (PPAR) gamma Partial Agonist and PPARdelta Antagonist Activity Suggests Their Antidiabetic Potential. J Med Chem 60, 7459-7475 DOI |
24 | Park HJ, Kim MK, Kim Y et al (2017) Gastrin-releasing peptide promotes the migration of vascular smooth muscle cells through upregulation of matrix metalloproteinase-2 and -9. BMB Rep 50, 628-633 DOI |
25 | Jung HJ, Im SS, Song DK, Bae JH (2017) ffects of chlorogenic acid on intracellular calcium regulation in lysophosphatidylcholine-treated endothelial cells. BMB Rep 50, 323-328 DOI |
26 | Chiang JY (2009) Bile acids: regulation of synthesis. J Lipid Res 50, 1955-1966 DOI |
27 | Chiang JY, Kimmel R, Weinberger C and Stroup D (2000) Farnesoid X receptor responds to bile acids and represses cholesterol 7alpha-hydroxylase gene (CYP7A1) transcription. J Biol Chem 275, 10918-10924 DOI |
28 | Hebert PR, Gaziano JM, Chan KS and Hennekens CH (1997) Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. Jama 278, 313-321 DOI |
29 | Jeong SJ, Lee MN and Oh GT (2017) The Role of Macrophage Lipophagy in Reverse Cholesterol Transport. Endocrinol Metab 32, 41-46 DOI |
30 | Weber C and Noels H (2011) Atherosclerosis: current pathogenesis and therapeutic options. Nat Med 17, 1410-1422 DOI |
31 | Pignone M, Phillips C and Mulrow C (2000) Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomised trials. BMJ 321, 983-986 DOI |
32 | Cheung BM and Lam KS (2010) Is intensive LDLcholesterol lowering beneficial and safe? Lancet 376, 1622-1624 DOI |
33 | Dembowski E and Davidson MH (2009) Statin and ezetimibe combination therapy in cardiovascular disease. Curr Opin Endocrinol Diabetes Obes 16, 183-188 DOI |
34 | Bonovas S, Nikolopoulos G and Sitaras NM (2011) Efficacy and safety of more intensive lowering of LDL cholesterol. Lancet 377, 715; author reply 715-716 |
35 | Tobert JA (2003) Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov 2, 517-526 DOI |
36 | Pedersen TR and Tobert JA (1996) Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: a reappraisal. Drug Saf 14, 11-24 DOI |
37 | Michos ED, Sibley CT, Baer JT, Blaha MJ and Blumenthal RS (2012) Niacin and statin combination therapy for atherosclerosis regression and prevention of cardiovascular disease events: reconciling the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes) trial with previous surrogate endpoint trials. J Am Coll Cardiol 59, 2058-2064 DOI |
38 | Leiva A, Guzman-Gutierrez E, Contreras-Duarte S et al (2017) Adenosine receptors: Modulators of lipid availability that are controlled by lipid levels. Mol Aspects Med 55, 26-44 DOI |
39 | Reiss AB and Cronstein BN (2012) Regulation of foam cells by adenosine. Arterioscler Thromb Vasc Biol 32, 879-886 DOI |
40 | Ohisalo JJ (1981) Effects of adenosine on lipolysis in human subcutaneous fat cells. J Clin Endocrinol Metab 52, 359-363 DOI |
41 | Chen JF, Eltzschig HK and Fredholm BB (2013) Adenosine receptors as drug targets--what are the challenges? Nat Rev Drug Discov 12, 265-286 DOI |